American International Group’s AN2 Therapeutics ANTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-5,362
Closed -$52.9K 3082
2023
Q1
$52.9K Buy
5,362
+107
+2% +$1.19K ﹤0.01% 2694
2022
Q4
$50.1K Buy
5,255
+2,976
+131% +$39.8K ﹤0.01% 2747
2022
Q3
$40K Buy
2,279
+108
+5% +$1.26K ﹤0.01% 2864
2022
Q2
$17K Buy
+2,171
New +$28.7K ﹤0.01% 3026

Other funds holding ANTX

American International Group's ANTX Position: Q2 2023 in Review

American International Group sold out of AN2 Therapeutics (ANTX) in Q2 2023, closing a stake of 5,362 shares — an estimated $52.9K sold.

American International Group first reported a position in ANTX in Q2 2022 and held it in 4 quarters. The position peaked at $52.9K in Q1 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q2 2023.

  • American International Group reported no remaining AN2 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • American International Group sold 5,362 AN2 Therapeutics shares in Q2 2023, an estimated $52.9K.
  • American International Group first reported a position in AN2 Therapeutics in Q2 2022 and held it in 4 quarters.
  • American International Group's AN2 Therapeutics position peaked at $52.9K in Q1 2023.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2023.

Based on American International Group's 13F filing for Q2 2023, filed 4 Aug 2023.